
Can Dr. Lal PathLabs sustain Q1's 19% growth as it scales acquisitions?
diagnostics · revenue growth · margin expansion

diagnostics · revenue growth · margin expansion

healthcare · hospital expansion · margin pressure

pharma · turnaround · Q2 FY27

consumer healthcare · pharma · margin expansion

FDC · buyback · tender offer

pharma earnings · revenue growth · minipress discontinuation

CDMO · peptide-expansion · FDA-approval

export growth · margin trajectory · Gennova integration


hospital expansion · revenue growth · ARPOB

pharma earnings · innovation portfolio · margin pressure

US generics · margin expansion · India growth

pharma cdmo · margin expansion · turnaround

crdmo · biologics contract loss · margin recovery

pharmaceutical apis · injectable facility ramp · margin compression

pharmaceuticals · margin expansion · share buyback

API pricing pressure · peptide CDMO · Genrx acquisition

peptide manufacturing · Genrx acquisition · Cenobamate launch

cdmo ramp · margin expansion · pharmaceutical exports

specialty chemicals · pharma intermediates · margin expansion

pharma · margin compression · ebitda guidance

cdmo · semaglutide · margin expansion

CDMO growth · pharma margins · API expansion

SPARC · Q2 FY27 · loss narrowing

change of control · formulations · Anupam Rasayan

operating margin · pharmacy retail · store expansion

margin pressure · raw material costs · growth deceleration


pharma manufacturing · subsidiary consolidation · margin compression

pharmaceuticals · margin expansion · international registrations